Apolipoprotein Testing
Advanced lipid testing measuring apoB and Lp(a) for more accurate cardiovascular risk assessment.
Evidence Summary
Apolipoprotein B (apoB) counts every atherogenic particle — LDL, VLDL, IDL and Lp(a) — in a single number, and 2025 evidence continues to support it as a more accurate cardiovascular risk marker than LDL-C. A 2025 systematic review of 593,354 people across 15 studies (Journal of Clinical Lipidology) found apoB outperformed LDL-C in all 9 head-to-head comparisons and bettered non-HDL-C in most. In the UK Biobank (41,099 adults, ~10-year follow-up; European Journal of Preventive Cardiology 2025), risk rose as apoB exceeded LDL particle number: the coronary artery disease hazard ratio reached about 2.5 at 30% discordance, while LDL particle-number discordance carried no significant excess risk. In 375,544 primary-prevention adults (European Journal of Preventive Cardiology 2025), "discordantly high" apoB carried higher MACE risk (HR 1.11) despite lower LDL-C. European guidelines already prioritize apoB; Lp(a) is a largely genetic, measure-once risk factor. For risk assessment only — not a diagnosis or treatment. Interpret results with a qualified clinician.
Evidence Scale
Mechanism of Action
ApoB is present as one molecule per atherogenic particle, so a single apoB level tallies the total number of LDL, VLDL, IDL and Lp(a) particles that drive atherosclerosis — capturing risk that LDL-cholesterol (a measure of cholesterol content, not particle count) can miss. Lp(a) is a largely genetically determined, independent cardiovascular risk factor. Together they give a more complete lipid-risk picture than a standard cholesterol panel.
Who Is This For?
Cardiovascular risk assessment, lipid optimization, family history of heart disease.
Protocol & Dosing
Dose
Single test with periodic monitoring (apoB). Lp(a) stable over life (test once).
Frequency
ApoB: annual, Lp(a): once
Duration
Periodic
Protocol Summary
Blood test for apoB and Lp(a). Include in comprehensive lipid panel.
Latest Evidence
2025: apoB confirmed as the sharper lipid-risk marker
A 2025 systematic review of 593,354 people across 15 studies (Journal of Clinical Lipidology) found apolipoprotein B outperformed LDL-C as a marker of atherosclerotic cardiovascular disease in all nine head-to-head comparisons, and bettered non-HDL-C in most. In the UK Biobank (41,099 adults, ~10-year follow-up; European Journal of Preventive Cardiology 2025), cardiovascular risk rose as apoB exceeded LDL particle number — the coronary artery disease hazard ratio reached about 2.5 at 30% discordance — while LDL particle-number discordance carried no significant excess risk. A separate 2025 analysis of 375,544 primary-prevention adults found that a 'discordantly high' apoB raised event risk (HR 1.11) even when LDL-C looked reassuring.
ApoB testing is a low-cost blood test used for cardiovascular risk assessment, not a diagnosis or treatment; a single test cannot capture individual risk on its own. Lp(a) is largely genetic and typically measured once. Targets and treatment decisions should be individualized with a qualified clinician. Educational information, not medical advice.
UK Biobank · 41,099 adults · ~10-yr follow-up · 2025
Risk climbs as ApoB outpaces LDL particle number
Hazard ratios for cardiovascular events as measured apoB exceeds LDL particle number (LDL-P); risk rose progressively with greater apoB excess, reaching a coronary artery disease hazard ratio of ~2.5 at 30% discordance, whereas LDL-P discordance showed no significant excess risk. Source: Epstein E, Ekpo E, Triffon D, et al. Apolipoprotein B outperforms LDL particle number as a marker of cardiovascular risk in the UK Biobank. Eur J Prev Cardiol. 2025.
Related on Peak Human
Diagnostic Testing
Advanced lipid panel including apoB and Lp(a) with physician interpretation.
Cardiovascular Biomarkers
Explore apoB, Lp(a), LDL-C and the markers that define lipid risk.
Heart Disease
How apoB-guided lipid management fits a prevention-first plan.
Optimization Service
Physician-supervised, biomarker-tracked lipid and metabolic optimization.
Vitamin K2 (MK-7) & Heart Health
Related reading on nutrients studied for cardiovascular and arterial health.
Longevity Research Insider
Dr. Goel's weekly review of new longevity and cardiometabolic research.
Key references: Epstein et al. — ApoB outperforms LDL particle number, UK Biobank, Eur J Prev Cardiol (2025) · Sehayek, Sniderman et al. — ApoB, LDL-C and non-HDL-C as risk markers, J Clin Lipidol (2025) · Du et al. — ApoB/LDL-C discordance in primary prevention (375,544 adults), Eur J Prev Cardiol (2025)
Interactions & Precautions
Contraindications
- None
Potential Risks
- •None
Potential Side Effects
Practitioner Notes
Clinical annotations from Dr. Goel
ApoB <60 mg/dL is a reasonable primary-prevention target and lower for high-risk patients; Lp(a) >50 nmol/L (>~125 nmol/L is high) raises risk and, being genetic, is measured once. 2025 discordance data reinforce ordering apoB rather than relying on LDL-C alone — a "normal" LDL-C with an elevated apoB still carries excess ASCVD risk. Elevated Lp(a) argues for more aggressive apoB lowering. Educational information for clinicians, not a treatment directive.
Dr. Sanjeev Goel
Chief Medical Officer, Peak Human
Cost & Access
Cost Range
$
Accessibility
Availability varies by location
Sample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation